These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34779063)

  • 1. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.
    Thyssen JP; Yosipovitch G; Paul C; Kwatra SG; Chu CY; DiBonaventura M; Feeney C; Zhang F; Myers D; Rojo R; Valdez H
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):434-443. PubMed ID: 34779063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.
    Cork MJ; McMichael A; Teng J; Valdez H; Rojo R; Chan G; Zhang F; Myers DE; DiBonaventura M
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):422-433. PubMed ID: 34743361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
    Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
    Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
    Thyssen JP; Bewley A; Ständer S; Castro C; Misery L; Kim BS; Biswas P; Chan G; Myers DE; Watkins M; Alderfer J; Güler E; Silverberg JI
    Dermatology; 2024; 240(2):243-253. PubMed ID: 38081155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
    Shi VY; Bhutani T; Fonacier L; Deleuran M; Shumack S; Valdez H; Zhang F; Chan GL; Cameron MC; Yin NC
    J Am Acad Dermatol; 2022 Aug; 87(2):351-358. PubMed ID: 35439608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
    Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
    Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
    Eichenfield LF; Flohr C; Sidbury R; Siegfried E; Szalai Z; Galus R; Yao Z; Takahashi H; Barbarot S; Feeney C; Zhang F; DiBonaventura M; Rojo R; Valdez H; Chan G
    JAMA Dermatol; 2021 Oct; 157(10):1165-1173. PubMed ID: 34406366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
    Reich K; Lio PA; Bissonnette R; Alexis AF; Lebwohl MG; Pink AE; Kabashima K; Boguniewicz M; Nowicki RJ; Valdez H; Zhang F; DiBonaventura M; Cameron MC; Clibborn C
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3228-3237.e2. PubMed ID: 36108923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
    Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
    Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
    Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Farooqui SA; Kerkmann U; Clibborn C
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2047-2055. PubMed ID: 37319109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
    JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib.
    Simpson EL; Wollenberg A; Bissonnette R; Silverberg JI; Papacharalambous J; Zhu L; Zhang W; Beebe JS; Vincent M; Peeva E; Bushmakin AG; Cappelleri JC; Chen L; Sikirica V; Xenakis J
    Dermatitis; 2021 Oct; 32(1S):S53-S61. PubMed ID: 33795561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
    Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V
    J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
    Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
    JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
    Ständer S; Bhatia N; Gooderham MJ; Silverberg JI; Thyssen JP; Biswas P; DiBonaventura M; Romero W; Farooqui SA
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1308-1317. PubMed ID: 35462428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.